OVERVIEW
The Global Preclinical Imaging (In-VIVO) Market is expected to hit USD 1.21 billion by 2025, rising by 5.01% to CAGR during the forecast period. The demand for the Preclinical Imaging (In-VIVO) Market is driven by factors such as robust R&D infrastructure for life science research, rapid adoption of new molecular imaging technologies, significant presence of pharmaceutical and biotechnology companies and increasing end user preference for multimodality systems.
TABLE OF CONTENT
1 Global Preclinical Imaging (In-VIVO) Market
1.1 Study Objectives
1.2 Market Definition
1.3 Study Scope
1.3.1 Markets Covered
1.3.2 Geographic Scope
2 RESEARCH METHODOLOGY
2.1 Research Data
2.1.1 Secondary Data
2.1.1.1 Key Data from Secondary Sources
2.1.2 Primary Data
2.1.2.1 Key Data from Primary Sources
2.1.2.2 Key Industry Insights
2.1.2.3 Breakdown of Primaries
2.2 Market Size Estimation
2.2.1 Bottom-Up Approach
2.2.2 Top-Down Approach
2.3 Market Breakdown and Data Triangulation
2.4 Research Assumptions
3 Global Preclinical Imaging (In-VIVO) Market – Executive Summary
3.1 Market Revenue, Market Size and Key Trends by Company
3.2 Key Trends by type of Application
3.3 Key Trends segmented by Geography
4 Global Preclinical Imaging (In-VIVO) Market – Comparative Analysis
4.1 Product Benchmarking – Top 10 companies
4.2 Top 5 Financials Analysis
4.3 Market Value split by Top 10 companies
4.4 Patent Analysis – Top 10 companies
4.5 Pricing Analysis
5 Global Preclinical Imaging (In-VIVO) Market – Industry Market Entry Scenario
5.1 Regulatory Framework Overview
5.2 New Business and Ease of Doing business index
5.3 Case studies of successful ventures
5.4 Customer Analysis – Top 10 companies
6 Global Preclinical Imaging (In-VIVO) Market – Market Forces
6.1 Introduction
6.2 Market Dynamics
6.2.1 Drivers
6.2.2 Opportunities
6.2.3 Challenges
6.3 Porters Analysis of Market
6.3.1 Bargaining power of suppliers
6.3.2 Bargaining powers of customers
6.3.3 Threat of new entrants
6.3.4 Rivalry among existing players
6.3.5 Threat of substitutes
7 Global Preclinical Imaging (In-VIVO) Market – Strategic Analysis
7.1 Value Chain analysis
7.2 Product Life Cycle
7.3 Supplier and distributor analysis (Market share and product dealing strategies)
8 Global Preclinical Imaging (In-VIVO) Market – By Modality (Market Size – & million/billion)
8.1 Micro-MRI Systems
8.2 Micro-Ultrasound Systems
8.3 Micro-CT Systems
8.4 Preclinical Photoacoustic Imaging Systems
8.5 Preclinical Magnetic Particle Imaging (MPI) Systems
8.6 Optical Imaging Systems
8.7 Preclinical Nuclear Imaging Systems
9 Global Preclinical Imaging (In-VIVO) Market – By Reagents
9.1 Preclinical Ultrasound Contrast Agents
9.2 Preclinical CT Contrast Agents
9.3 Preclinical MRI Contrast Agents
9.4 Preclinical Optical Imaging Reagents
9.5 Preclinical Nuclear Imaging Reagents
10 Global Preclinical Imaging (In-VIVO) Market – By Geography (Market Size – &
million/billion)
10.1 Introduction
10.2 North America
10.2.1 US
10.2.2 Canada
10.2.3 Mexico
10.3 Europe
10.3.1 U.K
10.3.2 Germany
10.3.3 Italy
10.3.4 France
10.3.5 Spain
10.3.6 Rest of Europe
10.4 Asia-Pacific
10.4.1 China
10.4.2 Japan
10.4.3 India
10.4.4 South Korea
10.4.5 Rest of APAC
10.5 Rest of the World
10.5.1 South America
10.5.2 Middle East
10.5.3 Africa
11 Global Preclinical Imaging (In-VIVO) Market – Entropy
11.1 New product launches
11.2 M&A’s, collaborations, JVs and partnerships
12 Global Preclinical Imaging (In-VIVO) Market -Company Profile (Key Players)
12.1 Market Share, Company Revenue, Products, M&A, Developments
12.2 Aspect Imaging Ltd.
12.3 Mediso Ltd.
12.4 Perkinelmer, Inc.
12.5 Li-Cor Biosciences
12.6 MR Solutions Ltd.
12.7 Milabs B.V.
12.8 Fujifilm Holdings Corporation
12.9 Miltenyi Biotec GmbH
12.10 Bruker Corporation
12.11 Trifoil Imaging
12.12 Company 11 & more
13 Global Preclinical Imaging (In-VIVO) Market – Appendix
13.1 Sources
13.2 Abbreviations